A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

Published:2017-12 Issue: Volume:87 Page:131-139
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Angevin Eric,Spitaleri Gianluca,Rodon Jordi,Dotti Katia,Isambert Nicolas,Salvagni Stefania,Moreno Victor,Assadourian Sylvie,Gomez Corinne,Harnois Marzia,Hollebecque Antoine,Azaro Analia,Hervieu Alice,Rihawi Karim,De Marinis Filippo

Funder

Sanofi

MSD

Bayer

Merck

Amgen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product;Bottaro;Science,1991

2. Met, metastasis, motility and more;Birchmeier;Nat Rev Mol Cell Biol,2003

3. Somatic mutations lead to an oncogenic deletion of met in lung cancer;Kong-Beltran;Cancer Res,2006

4. MET ampliﬁcation identiﬁes a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib;Lennerz;J Clin Oncol,2011

5. Impact of MET ampliﬁcation on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target;Lee;Oncol Rep,2011

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments;Frontiers in Oncology;2024-01-11

2. MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature;Therapeutic Advances in Medical Oncology;2024-01

3. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches;Cancers;2023-09-14

4. MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing;Drugs and Drug Candidates;2023-07-18

5. Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors;JTO Clinical and Research Reports;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3